CORDIS
EU research results

CORDIS

English EN
Identification, homing and monitoring of therapeutic cells for regenerative medicine – Identify, Enrich, Accelerate

Identification, homing and monitoring of therapeutic cells for regenerative medicine – Identify, Enrich, Accelerate

Objective

Regenerative medicine focuses on repairing or replacing tissue or organ function lost due to damage or congenital defects using appropriate cells for therapy that have healing capacities like stem cells or progenitor cells. Although regenerative medicine has the potential for more effective therapeutic interventions major improvement in three areas are still needed for a wider establishment of such new concepts in clinical practise: identification of the appropriate cells with healing capacity for the use in therapy, homing of these cells to the damaged tissue, and monitoring of the therapeutic intervention and effect. Thus, a multidisciplinary consortium has set up IDEA, a 60 month collaborative project to develop and establish:
• Photonic methods that allow a contact and marker-free identification and selection of cells with healing capacity for vascular, musculoskeletal and neuronal tissue defects;
• Magnetic cell select devices that capture and transport cells with healing potential through the circulatory system to damaged tissue and organs improving homing;
• Tracer and imaging technologies to monitor the therapeutic effects of interventional regenerative medicine by showing anatomic structure AND demonstrating cellular function using magnetic resonance imaging (MRI) and a new imaging technology known as magnetic particle imaging (MPI).
The IDEA project is intended to provide collaboration between scientists and clinicians from Karolinska Institute (Stockholm, Sweden), Kings College (London, UK), Paracelsus Medical University (Salzburg, Austria) and Julius-Maximilians-University (Würzburg, Germany) together with experts from SMEs specialized in photonic technologies for tissue engineering, medical device manufacturing with extensive experience in regulatory approval, the design, synthesis and up-scaling of nanoparticles for molecular imaging, and regulatory affairs. This multidisciplinary consortium will address scale-up, regulatory work and exploratory clinical investigations using the developed tools, technologies and devices in the time frame of the project.

Coordinator

TOPASS GMBH

Address

Drakestrasse 42
12205 Berlin

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 708 763,59

Administrative Contact

Ulrich Pison (Prof.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

NANOPET PHARMA GMBH

Germany

EU Contribution

€ 497 688

CONTRACT MEDICAL INTERNATIONAL SPOL SRO

Czechia

EU Contribution

€ 301 394,95

MICROMOD PARTIKELTECHNOLOGIE GMBH

Germany

EU Contribution

€ 494 158,88

MRB Forschungszentrum fur Magnet-Resonanz-Bayern e.V.

Germany

EU Contribution

€ 490 186,70

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 763 366,20

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 705 412,04

PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG

Austria

EU Contribution

€ 230 955,98

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 594 098,98

CELLTOOL GMBH

Germany

EU Contribution

€ 801 025,02

PROMOTOOL UNTERNEHMENSBERATUNG - DR THOMAS RUESCH

Germany

EU Contribution

€ 256 940,80

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 53 403,86

Project information

Grant agreement ID: 279288

Status

Closed project

  • Start date

    1 March 2012

  • End date

    28 February 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 662 775,57

  • EU contribution

    € 5 897 395

Coordinated by:

TOPASS GMBH

Germany